Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2021
Pharma News, 2021
Novartis’ canakinumab fails to improve overall survival in lung cancer trial
Novartis has announced that its interleukin-1beta (IL-1β) inhibitor canakinumab failed to hit the primary endpoint of overall survival in a Phase III non-small cell lung cancer (NSCLC)...
Moderna Announces First Participants Dosed in Study Evaluating COVID-19 Booster Vaccine Candidates
CAMBRIDGE, Mass.
Roche withdraws US indication for Tecentriq in bladder cancer
Swiss pharma company Roche has announced that it will withdraw the US indication for Tecentriq in prior-platinum treated metastatic urothelial carcinoma (mUC, bladder cancer).
Pfizer/BioNTech COVID-19 vaccine neutralizes Brazil variant in lab study
NEW YORK (Reuters) - The COVID-19 vaccine from Pfizer Inc and BioNTech SE was able to neutralize a new variant of the coronavirus spreading rapidly in Brazil, according to a laboratory study p...
Lupin launches generic diarrhea drug in US market
Drug major Lupin on Wednesday said it has launched Nitazoxanide tablets (500 mg), used to treat diarrhea, in the US market.
Indian drugmaker to pay $50mn in fine for destroying records before FDA inspection
Washington.
Teva Announces Launch of First Generic Version of AZOPT® (brinzolamide ophthalmic suspension) 1%, used to treat high pressure inside the eye, in the United States
TEL AVIV & PARSIPPANY, N.
New Drug Approval Could Be on Horizon for Alzheimer’s after 17-Year Drought
A drug to halt the progression of Alzheimer’s disease will likely be approved within the next three years, and Alzheon’s ALZ-801 might be the leading candidate.
Potential Blockbuster Drugs for 2021 – Alzheimer’s, Prostate Cancer and More
Drug DevelopmentClarivate published its annual “Drugs to Watch” list, and cited four drugs that it expects to be blockbusters—projected to bring in $1 billion in sales annually.
FDA Approves Gilead/Kite's Yescarta as First CAR-T for Follicular Lymphoma
The U.
Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19
A study out of Colombia investigated the effect of ivermectin on symptom duration in the setting of mild COVID-19 infection.
GSK, Vir hit as COVID-19 drug hopeful halted on possible weak efficacy in key NIH phase 3
GlaxoSmithKline and partner Vir Biotechnology have seen a key, late-stage test of their experimental COVID-19 drug stopped for new patients amid concerns it may not be working well enough.
60
61
62
63
64
65
66
67
68
